Morphic Holding, Inc. - Common Stock (NQ:MORF)

56.99 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Morphic Holding, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

Short Volatility Alert: Morphic Holding, Inc. ↗

May 27, 2022

On Thursday, shares of Morphic Holding, Inc. (NASDAQ: MORF) experienced volatile short activity. After the activity, the stock price went up +4.69% to $22.53. The overall...

Via Benzinga

Looking Into Morphic Holding's Return On Capital Employed ↗

May 20, 2022

Benzinga Pro data, Morphic Holding (NASDAQ:MORF) reported Q1 sales of $2.38 million. Earnings fell to a loss of $31.48 million, resulting in a 47.11% decrease from last quarter.

Via Benzinga

Morphic Holding: Q1 Earnings Insights ↗

May 04, 2022

Morphic Holding (NASDAQ:MORF) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

What 4 Analyst Ratings Have To Say About Morphic Holding ↗

May 05, 2022

Over the past 3 months, 4 analysts have published their opinion on Morphic Holding (NASDAQ:MORF) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Wells Fargo Maintains Overweight Rating for Morphic Holding: Here's What You Need To Know ↗

May 05, 2022

Wells Fargo has decided to maintain its Overweight rating of Morphic Holding (NASDAQ:MORF) and lower its price target from $81.00 to $79.00. Shares of Morphic Holding are trading down 3.76% over the...

Via Benzinga

71 Biggest Movers From Yesterday ↗

April 27, 2022

Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...

Via Benzinga

Stocks Flounder As Wall Street Rotates Out Of Tech ↗

April 26, 2022

Big Tech stocks are struggling ahead of several key earnings reports.

Via Talk Markets

34 Stocks Moving In Tuesday's Mid-Day Session ↗

April 26, 2022

Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday...

Via Benzinga

CFO And COO Of Morphic Holding Trades $2.2M In Company Stock ↗

October 18, 2021

Marc Schegerin, CFO And COO at Morphic Holding (NASDAQ:MORF), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A Form 4...

Via Benzinga

Topics Regulatory Compliance

The Past Week's Notable Insider Buys Include AppLovin, Cricut, Biotechs, And More ↗

August 21, 2021

With earnings-reporting season all but over, many insiders are free once more to buy or sell shares. Here are a few of the most noteworthy insider purchases that were reported in the past week.

Via Talk Markets

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022 ↗

March 31, 2022

Upgrades

Via Benzinga

The Past Week's Notable Insider Buys Included AppLovin, Cricut, Biotechs And More ↗

August 21, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders were making return trips to the buy window...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗

December 08, 2021

Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...

Via Benzinga

Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study ↗

July 09, 2021

Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD). The data...

Via Benzinga

The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week ↗

July 03, 2021

Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,...

Via Talk Markets

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗

July 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week ↗

July 03, 2021

Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few...

Via Benzinga

Notable Insider Buys Of The Last Week: Bumble, Coty, Peloton Interactive, More ↗

May 29, 2021

Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain or near all-time highs. Some return buyers were among the insiders...

Via Benzinga

Is Morphic Holding a Buy? ↗

April 14, 2021

This experimental biotech has more than tripled investors' money over the past 12 months.

Via The Motley Fool

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.